The control of hyperphosphataemia in haemodialysis patients (Journal article)
Papayianni, L./ Katopodis, K./ Kosmanou, J./ Banioti, A./ Katsaraki, A./ Palatzidou, M./ Prokopiou, F./ Betsiou, V./ Siamopoulos, K. C.
Patients with chronic uraemia develop various metabolic abnormalities, the most significant being the low production of vitamin D [1.25(OH)2D3] by the kidneys (1-3), hyperphosphataemia, and hypocalcaemia (4). These abnormalities, occurring usually in combination, are responsible for the pathogenesis of secondary hyperparathyroidism (HPT) (5-11). Prevention and treatment of secondary HPT can be achieved by means of administration of vitamin D and calcium. However, the above treatment is conditional on a low serum phosphorus concentration.
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Keywords:||Adult,Aged,Aluminum Hydroxide/*administration & dosage,Antacids/*administration & dosage,Chronic Disease,Drug Administration Schedule,Drug Monitoring,*Feeding Behavior,Female,Humans,Hyperparathyroidism, Secondary/blood/*drug therapy/etiology,Male,Middle Aged,Phosphates/blood,Renal Dialysis,Uremia/*complications|
|Appears in Collections:||Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)|
Files in This Item:
There are no files associated with this item.
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.